Roche | chemanager-online.com - Chemistry and Life Science

May. 22, 2020
News & Opinions
Roche Links with Vividion on E3 Ligases
Roche has signed a worldwide option and license agreement with Vividion Therapeutics, gaining access to the latter’s proteomics screening platform and proprietary small molecule library to target E3 ligases as well as a range of ...
Apr. 15, 2020
News & Opinions
Roche and Arrakis Link on RNA-targeted Drugs
Swiss drugmaker Roche has entered into a strategic collaboration and license agreement with US biopharma Arrakis Therapeutics for the discovery of RNA-targeted small molecule (rSM) drugs. ...
Feb. 21, 2020
News & Opinions
Roche Boosts Fibrotic Diseases with Promedior
Swiss pharma giant Roche has closed its acquisition of US clinical-stage biotech Promedior. Roche snapped up the Lexington, Massachusetts-based firm for an upfront cash payment of $390 million plus additional payments of up to $1 billion, ...
Dec. 06, 2019
Topics
Made in Switzerland – Exported Worldwide
The chemical, pharmaceutical and life sciences industries in Switzerland — organized in the Scienceindustries trade association — account for 45% of total exports with around 70,000 employees and are thus the undisputed ...
Jul. 25, 2019
News & Opinions
Sanofi Buys Nonprescription Rights to Tamiflu
Under an exclusive deal with Roche, French drugmaker Sanofi has secured non-prescription rights to the Swiss pharmaceutical giant’s now off-patent influenza drug Tamiflu in the US market.
Feb. 28, 2019
News & Opinions
Roche Pays $4.3 Billion for Spark Therapeutics
Swiss drugs giant Roche has agreed to pay $4.3 billion for Spark Therapeutics, marking the latest purchase of a biotech company by big pharma. ...
Dec. 11, 2018
News & Opinions
Gilead Nabs Roche Pharma Chief
Gilead Sciences has nabbed Daniel O’Day, head of Roche’s pharma business, as its new chief executive to replace current CEO John Milligan, with effective from March 2019. Both Milligan and Chairman John Martin have announced ...
Dec. 05, 2018
News & Opinions
FDA Greenlights Bayer-Loxo’s Vitrakvi
A new type of cancer treatment developed by a partnership of Bayer with biotech partner Loxo Oncology has won approval from the US Food and Drug Administration (FDA). Vitrakvi is recommended for patients whose tumors feature a neurotrophic ...
Sep. 21, 2018
Topics
A Wide Spectrum of Contract Services
With its pending $425-million acquisition of Halo Pharmaceuticals, Cambrex joins other contract providers that have used acquisitions in recent years to build end-to-to end service models that provide both active pharmaceutical ingredient ...
Sep. 04, 2018
News & Opinions
Affimed and Genentech in Immunotherapy Pact
German biopharma Affimed has agreed a strategic collaboration with Genentech, part of Swiss drug giant Roche, to develop immunotherapies for multiple cancers.

12 3 4 5 6 7 8…

Register now!

The latest information directly via newsletter.

GIT Verlag